Walkinshaw G - Search Results

1

HIF prolyl 4-hydroxylase-2 inhibition improves glucose and lipid metabolism and protects against obesity and metabolic dysfunction.

Rahtu-Korpela L, Karsikas S, Hörkkö S, Blanco Sequeiros R, Lammentausta E, Mäkelä KA, Herzig KH, Walkinshaw G, Kivirikko KI, Myllyharju J, Serpi R, Koivunen P. Rahtu-Korpela L, et al. Among authors: walkinshaw g. Diabetes. 2014 Oct;63(10):3324-33. doi: 10.2337/db14-0472. Epub 2014 May 1. Diabetes. 2014. PMID: 24789921

2

Transmembrane prolyl 4-hydroxylase is a fourth prolyl 4-hydroxylase regulating EPO production and erythropoiesis.

Laitala A, Aro E, Walkinshaw G, Mäki JM, Rossi M, Heikkilä M, Savolainen ER, Arend M, Kivirikko KI, Koivunen P, Myllyharju J. Laitala A, et al. Among authors: walkinshaw g. Blood. 2012 Oct 18;120(16):3336-44. doi: 10.1182/blood-2012-07-441824. Epub 2012 Sep 5. Blood. 2012. PMID: 22955912 Free article.

3

Hypoxia-Inducible Factor Prolyl 4-Hydroxylase-2 Inhibition Protects Against Development of Atherosclerosis.

Rahtu-Korpela L, Määttä J, Dimova EY, Hörkkö S, Gylling H, Walkinshaw G, Hakkola J, Kivirikko KI, Myllyharju J, Serpi R, Koivunen P. Rahtu-Korpela L, et al. Among authors: walkinshaw g. Arterioscler Thromb Vasc Biol. 2016 Apr;36(4):608-17. doi: 10.1161/ATVBAHA.115.307136. Epub 2016 Feb 4. Arterioscler Thromb Vasc Biol. 2016. PMID: 26848160

4

Systemic inactivation of hypoxia-inducible factor prolyl 4-hydroxylase 2 in mice protects from alcohol-induced fatty liver disease.

Laitakari A, Ollonen T, Kietzmann T, Walkinshaw G, Mennerich D, Izzi V, Haapasaari KM, Myllyharju J, Serpi R, Dimova EY, Koivunen P. Laitakari A, et al. Among authors: walkinshaw g. Redox Biol. 2019 Apr;22:101145. doi: 10.1016/j.redox.2019.101145. Epub 2019 Feb 19. Redox Biol. 2019. PMID: 30802717 Free PMC article.

5

HIF-P4H-2 inhibition enhances intestinal fructose metabolism and induces thermogenesis protecting against NAFLD.

Laitakari A, Tapio J, Mäkelä KA, Herzig KH, Dengler F, Gylling H, Walkinshaw G, Myllyharju J, Dimova EY, Serpi R, Koivunen P. Laitakari A, et al. Among authors: walkinshaw g. J Mol Med (Berl). 2020 May;98(5):719-731. doi: 10.1007/s00109-020-01903-0. Epub 2020 Apr 15. J Mol Med (Berl). 2020. PMID: 32296880 Free PMC article.

6

Activation of the hypoxia response pathway protects against age-induced cardiac hypertrophy.

Röning T, Magga J, Laitakari A, Halmetoja R, Tapio J, Dimova EY, Szabo Z, Rahtu-Korpela L, Kemppi A, Walkinshaw G, Myllyharju J, Kerkelä R, Koivunen P, Serpi R. Röning T, et al. Among authors: walkinshaw g. J Mol Cell Cardiol. 2022 Mar;164:148-155. doi: 10.1016/j.yjmcc.2021.12.003. Epub 2021 Dec 14. J Mol Cell Cardiol. 2022. PMID: 34919895 Free article.

7

Contribution of HIF-P4H isoenzyme inhibition to metabolism indicates major beneficial effects being conveyed by HIF-P4H-2 antagonism.

Tapio J, Halmetoja R, Dimova EY, Mäki JM, Laitala A, Walkinshaw G, Myllyharju J, Serpi R, Koivunen P. Tapio J, et al. Among authors: walkinshaw g. J Biol Chem. 2022 Aug;298(8):102222. doi: 10.1016/j.jbc.2022.102222. Epub 2022 Jul 1. J Biol Chem. 2022. PMID: 35787374 Free PMC article.

8

Inhibition of HIF prolyl-4-hydroxylases by FG-4497 reduces brain tissue injury and edema formation during ischemic stroke.

Reischl S, Li L, Walkinshaw G, Flippin LA, Marti HH, Kunze R. Reischl S, et al. Among authors: walkinshaw g. PLoS One. 2014 Jan 7;9(1):e84767. doi: 10.1371/journal.pone.0084767. eCollection 2014. PLoS One. 2014. PMID: 24409307 Free PMC article.

9

Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.

Del Balzo U, Signore PE, Walkinshaw G, Seeley TW, Brenner MC, Wang Q, Guo G, Arend MP, Flippin LA, Chow FA, Gervasi DC, Kjaergaard CH, Langsetmo I, Guenzler V, Liu DY, Klaus SJ, Lin A, Neff TB. Del Balzo U, et al. Among authors: walkinshaw g. J Pharmacol Exp Ther. 2020 Aug;374(2):342-353. doi: 10.1124/jpet.120.265181. Epub 2020 Jun 2. J Pharmacol Exp Ther. 2020. PMID: 32487538

10

HIF-1α is required for hematopoietic stem cell mobilization and 4-prolyl hydroxylase inhibitors enhance mobilization by stabilizing HIF-1α.

Forristal CE, Nowlan B, Jacobsen RN, Barbier V, Walkinshaw G, Walkley CR, Winkler IG, Levesque JP. Forristal CE, et al. Among authors: walkinshaw g. Leukemia. 2015 Jun;29(6):1366-78. doi: 10.1038/leu.2015.8. Epub 2015 Jan 12. Leukemia. 2015. PMID: 25578474 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

29 results

Search Page

Filters